IHC 7 Markers Therapy Prediction | Lahalak Platform
Assessing tumor response potential to modern immunotherapies by analyzing 7 markers, helping select patients who will benefit most while avoiding ineffective treatment options.
Scientific name: Immunohistochemistry (IHC) Interpretation and Consultation (7 Markers)
A specialized immuno-oncology consultative package is based on the integrated analysis of seven immunohistochemical (IHC) markers designed to assess the tumor immune microenvironment (TIME) and predict the response to immune checkpoint inhibitors (ICIs). The package typically includes: immune activation markers (such as CD8 and Granzyme B), immune...
Service type
Medical Consultation (Tissue Analysis)
Duration
30-45 minutes
Fasting
Fasting is not required
Included Services
- Integrated analysis of seven immunological markers to assess the tumor's micro-immunological environment.
- Quantitative measurements of immune infiltration and checkpoint expression using advanced image analysis.
- Consult with a pathologist specializing in tumor immunology to interpret the results and classify the immunophenotype.
- Issue the "Immunological Characterization and Immune Response Prediction Report" with immunophenotype and recommendations.
- Personal support services from Halak.
Medical Service Information
Conditions & Notices
- Knowing the type of immunotherapy to be evaluated: to select the correct antibody for PD-L1 (example: 22C3 for pembrolizumab, SP142 for atezolizumab).
- A recent and representative tissue sample: The biopsy should ideally be recent and before any immunotherapy, as the therapy may alter immune expression.
- Submit all reports: Attach the seven mark reports.
- No need for new samples or fasting.
- Expected duration: 10 to 20 working days due to the analytical and quantitative complexity.
Medical services you might also like